Managing Haemophilic Arthropathy in People With Haemophilia in Japan: An Informal Consensus.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Kumiko Ono has received honoraria from Chugai Pharmaceutical Co., Ltd. and Sanofi K.K. Azusa Nagao has received investigator‐initiated research/education grant funding from Bayer Yakuhin Ltd., Pfizer Japan Inc., and Chugai Pharmaceutical Co., Ltd. and honoraria from Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Fujimoto Pharmaceutical Corporation, KM Biologics, Pfizer Japan Inc., Novo Nordisk Pharma Ltd., and CSL Behring; and is a medical advisor for Chugai Pharmaceutical Co., Ltd. and KM Biologics. Yusuke Inagaki has received specified clinical trial funding from MediaMart Co., Ltd.; research funding from Chugai Pharmaceutical Co., Ltd., Johnson & Johnson K.K., KM Biologics, Olympus Terumo Biomaterials Corp., and Zimmer Biomet; and honoraria from Asahi Kasei Pharma Corporation, Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Healios K.K., Hisamitsu Pharmaceutical Co., Johnson & Johnson K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd.; and is a medical advisor for Chugai Pharmaceutical Co., Ltd. and KM Biologics. Kagehiro Amano has received research funding from KM Biologics; consulting fees from Chugai Pharmaceutical Co., Ltd.; and payment or honoraria from Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Novo Nordisk Pharma Ltd., KM Biologics, Japan Blood Products Organization, Sanofi K.K., Takeda Pharmaceutical Co., Ltd., CSL Behring, Pfizer Japan Inc., and Fujimoto Pharmaceutical Corporation; has participated on a safety monitoring board or advisory board for Chugai Pharmaceutical Co., Ltd.; and is an endowed chair for CSL Behring. Miwa Goto has received honoraria for speakers’ bureaus from Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., CSL Behring, and Novo Nordisk Pharma Ltd. Chiai Nagae has received honoraria for speakers' bureaus from Chugai Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. Akihiro Sawada has received payment or honoraria from Chugai Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., CSL Behring, Sanofi K.K., KM Biologics, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd. Rie Shirayama has received consulting fees from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., and Pfizer Japan Inc., and honoraria for speakers bureaus from Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Novo Nordisk Pharma Ltd., KM Biologics, CSL Behring, and Fujimoto Pharmaceutical Corporation; has participated on advisory boards for Chugai Pharmaceutical Co., Ltd. and Sanofi K.K.; and the institution that employs Rie Shirayama has received grants from Chugai Pharmaceutical Co., Ltd. Nobuaki Suzuki has received payment or honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sanofi K.K., Novo Nordisk Pharma Ltd., CSL Behring, Bayer Yakuhin Ltd., Pfizer Japan Inc., Japan Blood Products Organization, and KM Biologics. Masahiro Takeyama has received payment or honoraria from Chugai Pharmaceutical Co., Ltd., CSL Behring, Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, Bayer Yakuhin Ltd., and Pfizer Japan Inc.; has received investigator‐initiated research grant funding from Chugai Pharmaceutical Co., Ltd. and Japan Blood Products Organization; and has participated on advisory boards for Chugai Pharmaceutical Co., Ltd. and Sanofi K.K. Hideyuki Takedani has received honoraria from Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd.; has an advisory role with Novo Nordisk Pharma Ltd., and Chugai Pharmaceutical Co., Ltd.; has received honoraria for speakers’ bureaus from Bayer Yakuhin Ltd., Chugai Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd., Sanofi K.K., KM Biologics, and Asahi Kasei Corporation. Makoto Kaneda, Kenichiro Makino, and Naoya Yamasaki have no conflicts of interest to declare. 17. BMC Pediatr. 2020 Apr 20;20(1):173. doi: 10.1186/s12887-020-02071-3. Treatment with radiosynoviorthesis in hemophilic patients with and without inhibitor. Tena-Sanabria ME(1), Rojas-Sato YF(2), Castañeda-Resendiz JC(2), Fuentes-Herrera G(2), Álvarez-Martínez FA(2), Tena-Gonzalez YI(2), Núñez-Enríquez JC(3). Author information: (1)Orthopedics Department, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. dulce.bustamante@permanyer.com. (2)Orthopedics Department, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. (3)Medical Research Unit in Clinical Epidemiology, UMAE Hospital de Pediatría "Dr. Silvestre Frenk Freund", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. BACKGROUND: Spontaneous bleedings occurring into joints (hemarthrosis) are the most common manifestations of hemophilia and causes severe joint damage ultimately resulting in joint disfunction known as hemophilic arthropathy. Among available therapeutic options for reducing recurrent hemarthrosis-associated damage, radiosynoviorthesis (RS) has proven effective in improving joint function. AIM: To assess the impact of RS with Yttrium(90) citrate (C-Y(90)) on frequency of hemarthroses and joint function in a group of pediatric patients. METHODS: Between November 1998 and February 2017, we evaluated 27 pediatric patients with mild, moderate or severe hemophilia with haemophilic arthropathy. Overall, RS was applied in 60 joints. Some patients received more than one single intra-articular injection with C-Y(90). RESULTS: During the follow-up, one patient showed joint bleeding 15 months after RS, one patient after 12 months and one patient after 45 days. The episodes of hemarthrosis were reduced and joint function significantly improved in all patients. CONCLUSION: RS with C-Y(90) is a simple and safe treatment for reducing the frequency of hemarthroses in patients with hemophilia. It decreases the use of factor VIII / IX and improves joint function. DOI: 10.1186/s12887-020-02071-3 PMCID: PMC7168877